Abstract | OBJECTIVE:
Interferon alpha (IFN-alpha) with or without ribavirin is an approved therapy for patients with chronic hepatitis C. However, a sustained response is achieved in less than 40% of all treated cases. Retreatment of relapsers or non-responders usually fails. Thymosin alpha 1 (Ta-1) is a polypeptide with immunomodulatory properties that has been suggested to increase response rates in patients with chronic hepatitis C. The aim of present study was to evaluate the efficacy of a novel triple regimen which includes Ta-1 for relapsers and non-responders to the combination of TA-1 and ribavirin. METHODS: In the present study, 11 patients who relapsed (n=5) or did not respond (n=6) to previous INF-alpha-based therapy were retreated with combination Ta-1, INF-alpha and ribavirin for 12 months, and followed up for a further six months. RESULTS: Four out of five relapsers had a sustained response. One of the non-responders cleared the HCV RNA during the post-treatment follow-up. Minor adverse effects were observed during treatment with this combination therapy and no dose reduction or discontinuations were needed. CONCLUSION:
|
Authors | Z Abbas, S S Hamid, S Tabassum, W Jafri |
Journal | JPMA. The Journal of the Pakistan Medical Association
(J Pak Med Assoc)
Vol. 54
Issue 11
Pg. 571-4
(Nov 2004)
ISSN: 0030-9982 [Print] Pakistan |
PMID | 15623184
(Publication Type: Journal Article)
|
Chemical References |
- Adjuvants, Immunologic
- Antiviral Agents
- Interferon-alpha
- Ribavirin
- Thymosin
- Thymalfasin
|
Topics |
- Adjuvants, Immunologic
(therapeutic use)
- Adult
- Antiviral Agents
(therapeutic use)
- Drug Therapy, Combination
- Female
- Hepatitis C, Chronic
(drug therapy, immunology)
- Humans
- Interferon-alpha
(therapeutic use)
- Male
- Middle Aged
- Retreatment
- Ribavirin
(therapeutic use)
- Thymalfasin
- Thymosin
(analogs & derivatives, therapeutic use)
|